Упрощенная HTML-версия
191
109.
Perri F. Role of interleukin polymorphisms in gastric cancer: "Pros
and cons" / F. Perri [et al.] // World journal of gastrointestinal oncology. –
2010. – Vol. 2, № 6. – P. 265-271.
110.
Perri F. Cytokine gene polymorphisms in gastric cancer patients from
two Italian areas at high and low cancer prevalence / F. Perri [et al.]
//Cytokine. – 2005. – Vol.30, №.5. – P.293-302.
111.
Persson C. Interleukin 1-beta gene polymorphisms and risk of gastric
cancer in Sweden / C. Persson [et al.] //Scandinavian journal of
gastroenterology. – 2009. – Vol. 44, №3. – P.339-345.
112.
Quiding-Järbrink
M.
Decreased IgA antibody production in
the stomach of gastric adenocarcinoma patients / M. Quiding-Järbrink [et al.]
//
– 2009. – Vol. 131, № 3. – P. 463-461.
113.
Ramírez-Mendoza P. Concordance between pathologists in the
diagnosis of gastric atrophy according with the OLGA system / P. Ramírez-
Mendoza [et al.] // Revista de gastroenterología de México. – 2009. – Vol.74,
№2. – P.88-93.
114.
Ramírez-Mendoza P. Evaluation of Gastric Atrophy. Comparison
between Sidney and OLGA Systems / P. Ramírez-Mendoza [et al.] // Revista
médica del Instituto Mexicano del Seguro Social. – 2008. – Vol.46, №2. –
P.135-139.
115.
Rugge M. Gastritis OLGA-staging and gastric cancer risk: a twelve-
year clinico-pathological follow-up study / M. Rugge [et al.] // Journal of
gastroenterology. – 2010. – Vol. 31, № 10. – P. 1104-1111.
116.
Rugge M. OLGA staging for gastritis: A tutorial / M. Rugge [et al.] //
Digestive and liver disease. – 2008. – Vol.40, №8. – P.650-658.
117.
Rugge M. Gastritis staging in clinical practice: the OLGA staging
system / M. Rugge [et al.] //Gut. – 2007. – Vol.56, №5. – P.631-636.